About Dr. Qin Huanlong
Dr. Qin Huanlong (秦环龙) is a Professor, Doctoral Supervisor, and one of China's most distinguished colorectal surgeons and intestinal medicine specialists, based at the Department of General Surgery, Changhai Hospital, Naval Medical University (Second Military Medical University). He is recognized nationally and internationally as a leading authority on colorectal cancer surgery, inflammatory bowel disease (IBD), intestinal failure, and — uniquely among China's senior surgeons — the clinical application of intestinal microbiome science, including fecal microbiota transplantation (FMT), to the management of a broad spectrum of gastrointestinal and systemic diseases. His career has bridged the traditional domains of colorectal surgery and gastroenterology, producing a body of clinical and research work that has shaped both surgical practice and the emerging field of microbiome-based therapeutics in China.
Dr. Qin's dual expertise — as a technically accomplished colorectal surgeon and as a pioneer of microbiome medicine in China — makes him a uniquely valuable resource for international patients with complex colorectal and intestinal conditions. For patients with colorectal cancer requiring surgical resection, his expertise in laparoscopic and robotic colorectal surgery, total mesorectal excision (TME) for rectal cancer, and sphincter-preserving techniques ensures access to the highest standard of oncological colorectal surgery. For patients with IBD, intestinal failure, recurrent Clostridioides difficile infection, or other conditions amenable to microbiome-based intervention, his leadership of one of China's most active FMT programs provides access to therapeutic options that are not widely available outside specialized centers.
Hospital Affiliation: Department of General Surgery, Changhai Hospital
Changhai Hospital (长海医霂), affiliated with Naval Medical University, is one of Shanghai's largest and most prestigious academic medical centers. Its Department of General Surgery is a high-volume, multidisciplinary surgical program with particular national recognition in colorectal surgery, hepatobiliary surgery, and gastrointestinal oncology. The colorectal surgery division performs a high volume of laparoscopic and robotic colorectal resections annually, supported by a dedicated colorectal cancer multidisciplinary team integrating colorectal surgery, medical oncology, radiation oncology, interventional radiology, and gastroenterology for comprehensive colorectal cancer management.
The department's intestinal microbiome and FMT program — one of the most active and scientifically rigorous in China — is equipped with a dedicated FMT laboratory for donor screening, stool processing, and preparation of standardized FMT capsules and enema preparations, and maintains an active clinical trials program evaluating FMT and microbiome-based interventions for a broad range of indications including recurrent C. difficile infection, IBD, irritable bowel syndrome, metabolic disease, and neurological conditions. The program's research infrastructure includes a dedicated intestinal microbiome biobank and a translational research laboratory focused on the mechanisms of microbiome-host interaction and the development of next-generation microbiome therapeutics.
Clinical Specialties: What Dr. Qin Huanlong Treats
- Colorectal cancer surgery — laparoscopic and robotic right hemicolectomy, left hemicolectomy, sigmoid colectomy, and anterior resection for colon cancer; laparoscopic and robotic total mesorectal excision (TME) for rectal cancer with sphincter preservation; intersphincteric resection (ISR) for ultra-low rectal cancer; abdominoperineal resection (APR) for low rectal cancer not amenable to sphincter preservation; transanal TME (TaTME) for technically challenging rectal cancers; lateral lymph node dissection for rectal cancer with lateral nodal involvement; coordination with medical oncology and radiation oncology for neoadjuvant and adjuvant treatment
- Inflammatory bowel disease (IBD) surgery — laparoscopic total proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis; subtotal colectomy for acute severe ulcerative colitis; segmental resection and strictureplasty for Crohn's disease; management of IBD complications including fistula, abscess, and obstruction; coordination with gastroenterology for perioperative medical management and postoperative IBD surveillance
- Fecal microbiota transplantation (FMT) — FMT for recurrent and refractory Clostridioides difficile infection (CDI); FMT for ulcerative colitis and Crohn's disease; FMT for irritable bowel syndrome with diarrhea (IBS-D); FMT for metabolic syndrome and obesity; FMT for hepatic encephalopathy; investigational FMT for neurological and psychiatric conditions including autism spectrum disorder and Parkinson's disease; standardized FMT capsule preparation and colonoscopic FMT delivery; donor screening and microbiome profiling
- Intestinal failure and short bowel syndrome — surgical management of short bowel syndrome including intestinal lengthening procedures (STEP, Bianchi); parenteral nutrition management and weaning; intestinal rehabilitation programs; coordination with nutrition support teams for long-term enteral and parenteral nutrition management; intestinal transplantation evaluation and referral
- Anorectal surgery — surgical management of complex anal fistula including ligation of intersphincteric fistula tract (LIFT), advancement flap repair, and video-assisted anal fistula treatment (VAAFT); hemorrhoidectomy and stapled hemorrhoidopexy; rectocele and rectal prolapse repair; sacral nerve stimulation for fecal incontinence
- Intestinal microbiome assessment and microbiome-based therapeutics — comprehensive gut microbiome profiling by 16S rRNA sequencing and shotgun metagenomics; microbiome-based dietary and probiotic intervention; FMT capsule therapy; coordination with the microbiome research program for access to investigational microbiome therapeutics through clinical trials
- Colorectal cancer screening and surveillance — colonoscopic surveillance for patients at elevated colorectal cancer risk including Lynch syndrome, familial adenomatous polyposis (FAP), and prior colorectal cancer; coordination with the gastroenterology endoscopy team for polypectomy and EMR of colorectal polyps
Intestinal Microbiome Medicine: A Frontier at Changhai Hospital
Dr. Qin Huanlong's contributions to the development of microbiome medicine in China extend well beyond his clinical FMT practice. His research program at Changhai Hospital has produced foundational studies on the composition and function of the human gut microbiome in health and disease, the mechanisms by which FMT restores microbiome homeostasis, and the clinical efficacy of FMT and microbiome-based interventions across a broad range of indications. His publications in peer-reviewed journals — including contributions to Gut, Gastroenterology, Journal of Crohn's and Colitis, Cell Host & Microbe, and Chinese Medical Journal — have been widely cited and have contributed to the international evidence base for FMT and microbiome therapeutics.
His leadership of Changhai Hospital's FMT program — one of the largest and most scientifically rigorous in Asia — has established it as a national reference center for microbiome-based therapeutics, attracting patients and research collaborators from across China and internationally. For international patients with recurrent C. difficile infection, refractory IBD, or other conditions amenable to FMT, Changhai Hospital's program offers access to standardized, high-quality FMT delivered by an experienced team with a deep understanding of the microbiome science underlying the treatment.
Why International Patients Choose Dr. Qin Huanlong and Changhai Hospital
International patients seek consultation with Dr. Qin Huanlong for two distinct but complementary reasons: his expertise as a colorectal surgeon, and his unique position as one of China's leading microbiome medicine specialists.
For patients with colorectal cancer requiring surgical resection, Dr. Qin's expertise in laparoscopic and robotic colorectal surgery — including TaTME for technically challenging rectal cancers and ISR for ultra-low rectal cancer — provides access to the most advanced minimally invasive colorectal surgical techniques, with the sphincter preservation rates and oncological outcomes that are the hallmarks of a high-volume, specialized colorectal surgery program. The combination of surgical expertise and multidisciplinary oncological support at Changhai Hospital ensures that colorectal cancer patients receive not only excellent surgery but also optimal perioperative medical oncological and radiation oncological management.
For patients with recurrent C. difficile infection — a condition that causes enormous suffering and is increasingly resistant to antibiotic therapy — FMT at Changhai Hospital offers cure rates exceeding 85–90% after a single treatment, at a fraction of the cost of repeated antibiotic courses and with a safety profile that is well established in the international literature. For patients with refractory ulcerative colitis or Crohn's disease who have not responded to biological therapies, FMT at Changhai Hospital provides access to a therapeutic option that is supported by a growing body of clinical trial evidence and that may achieve remission in patients who have exhausted standard medical therapies.
The cost of colorectal surgical consultation, FMT, and microbiome assessment at Changhai Hospital is substantially below that of equivalent services in Western healthcare systems, and access to Dr. Qin's clinic can typically be arranged within days through CMCS.
What to Expect at Your Consultation
Consultations with Dr. Qin Huanlong at Changhai Hospital arranged through CMCS begin with a comprehensive review of all prior colorectal or intestinal investigation — including colonoscopy reports and biopsy pathology, CT colonography, MRI pelvis for rectal cancer staging, prior surgical records, IBD disease history and prior medical therapy records, C. difficile testing results, and relevant laboratory investigations — as well as the patient's gastrointestinal symptom history, current medications, and nutritional status. CMCS will arrange certified translation of all medical records and investigation results in advance of the consultation.
Dr. Qin will assess the colorectal or intestinal pathology, evaluate surgical indication and approach or FMT candidacy, outline the recommended treatment strategy with detailed rationale, and coordinate multidisciplinary tumor board review for colorectal cancer cases. A written English-language consultation summary is provided after every appointment, and CMCS will facilitate direct communication between Dr. Qin's team and the patient's home gastroenterologist or colorectal surgeon for continuity of care planning.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking colorectal surgical or microbiome medicine consultation with Dr. Qin Huanlong at Changhai Hospital. Our services include priority consultation scheduling, certified medical record and investigation result translation, coordination of additional investigations including colonoscopy, MRI pelvis, and microbiome profiling, on-site interpretation throughout the consultation, surgical logistics and hospital admission coordination, FMT procedure coordination, and written English-language reporting of all findings and recommendations. CMCS will also facilitate direct communication between Dr. Qin's team and the patient's home physicians to ensure seamless continuity of care.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0 comentarios